Nurix Therapeutics and biotech Seagen are combining their expertise to work on an emerging class of anticancer therapeutics known as degrader–antibody conjugates (DACs).
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
24,99 € / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
209,00 € per year
only 17,42 € per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Log in
Learn about institutional subscriptions
Read our FAQs
Contact customer support
About this article
Cite this article
New guise ADCs couple antibodies to degraders.
Nat Biotechnol41, 1360 (2023). https://doi.org/10.1038/s41587-023-02001-5
Download citation
Published: 12 October 2023
Issue Date: October 2023
DOI: https://doi.org/10.1038/s41587-023-02001-5
>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : Nature.com – https://www.nature.com/articles/s41587-023-02001-5
